YAP enhances the pro-proliferative transcriptional activity of mutant p53 proteins

EMBO Reports

Volumn 17, Issue 2, 2016, Pages 188-201

  Di Agostino, Silvia ^a   Sorrentino, Giovanni ^b,c   Ingallina, Eleonora ^b,c   Valenti, Fabio ^a   Ferraiuolo, Maria ^a   Bicciato, Silvio ^d   Piazza, Silvano ^b   Strano, Sabrina ^a   Del Sal, Giannino ^b,c   Blandino, Giovanni ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b Laboratorio Nazionale CIB LNCIB   (Italy)

^c UNIVERSITY OF TRIESTE   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

gene expression; metabolism; mutant p53 and YAP; proliferation; statin

Indexed keywords

CYCLIN A; CYCLIN B; CYCLIN DEPENDENT KINASE 1; NUCLEAR FACTOR Y; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; CDK1 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; PHOSPHOPROTEIN; PROTEIN BINDING; SIGNAL TRANSDUCING ADAPTOR PROTEIN; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ARTICLE; BINDING AFFINITY; BREAST CANCER; CANCER CELL; CELL GROWTH; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; EXTRACT; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REGULATOR GENE; TATA BOX; TRANSCRIPTION REGULATION; WESTERN BLOTTING; BREAST TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HCT 116 CELL LINE; MCF-7 CELL LINE; METABOLISM; MUTATION; PROTEIN TRANSPORT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; BREAST NEOPLASMS; CELL PROLIFERATION; CYCLIN A; CYCLIN B; CYCLIN-DEPENDENT KINASES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HUMANS; MCF-7 CELLS; MUTATION; PHOSPHOPROTEINS; PROTEIN BINDING; PROTEIN TRANSPORT; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84957440360     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.15252/embr.201540488     Document Type: Article

References (65)

1. Walerych D, Napoli M, Collavin L, Del Sal G, (2012) The rebel angel: mutant p53 as the driving oncogene in breast cancer. Carcinogenesis 33: 2007-2017
2. Muller PA, Vousden KH, (2013) p53 mutations in cancer. Nat Cell Biol 15: 2-8
3. Brosh R, Rotter V, (2009) When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer 9: 701-713
4. Di Agostino S, Strano S, Emiliozzi V, Zerbini V, Mottolese M, Sacchi A, Blandino G, Piaggio G, (2006) Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. Cancer Cell 10: 191-202
5. Blandino G, Levine AJ, Oren M, (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene 18: 477-485
6. Freed-Pastor WA, Prives C, (2012) Mutant p53: one name, many proteins. Genes Dev 26: 1268-1286
7. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, et al, (2009) A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137: 87-98
8. Girardini JE, Napoli M, Piazza S, Rustighi A, Marotta C, Radaelli E, Capaci V, Jordan L, Quinlan P, Thompson A, et al, (2011) A Pin1/mutant p53 axis promotes aggressiveness in breast cancer. Cancer Cell 20: 79-91
9. Lang GA, Iwakuma T, Suh YA, Liu G, Rao VA, Parant JM, Valentin-Vega YA, Terzian T, Caldwell LC, Strong LC, et al, (2004) Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119: 861-872
10. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, Crowley D, Jacks T, (2004) Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119: 847-860
11. Donehower LA, Lozano G, (2009) 20 years studying p53 functions in genetically engineered mice. Nat Rev Cancer 9: 831-841
12. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, Theillet C, Rodriguez C, Lidereau R, Bièche I, et al, (2006) The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 12: 1157-1167
13. Goh AM, Coffill CR, Lane DP, (2011) The role of mutant p53 in human cancer. J Pathol 223: 116-126
14. Bougeard G, Sesboüé R, Baert-Desurmont S, Vasseur S, Martin C, Tinat J, Brugières L, Chompret A, de Paillerets BB, Stoppa-Lyonnet D, et al, (2008) Molecular basis of the Li-Fraumeni syndrome: an update from the French LFS families. J Med Genet 45: 535-538
15. Girardini JE, Marotta C, Del Sal G, (2014) Disarming mutant p53 oncogenic function. Pharmacol Res 79: 75-87
16. Sampath J, Sun D, Kidd VJ, Grenet J, Gandhi A, Shapiro LH, Wang Q, Zambetti GP, Schuetz JD, (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. J Biol Chem 276: 39359-39367
17. Stambolsky P, Tabach Y, Fontemaggi G, Weisz L, Maor-Aloni R, Siegfried Z, Shiff I, Kogan I, Shay M, Kalo E, et al, (2010) Modulation of the vitamin D3 response by cancer-associated mutant p53. Cancer Cell 17: 273-285
18. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, et al, (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148: 244-258
19. Sorrentino G, Comel A, Mantovani F, Del Sal G, (2014) Regulation of mitochondrial apoptosis by Pin1 in cancer and neurodegeneration. Mitochondrion 19 (Pt A): 88-96
20. Bertini E, Oka T, Sudol M, Strano S, Blandino G, (2009) YAP: at the crossroad between transformation and tumor suppression. Cell Cycle 8: 49-57
21. Pan D, (2010) The hippo signaling pathway in development and cancer. Dev Cell 19: 491-505
22. Johnson R, Halder G, (2014) The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 13: 63-79
23. Pegoraro S, Ros G, Ciani Y, Sgarra R, Piazza S, Manfioletti G, (2015) A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness. Oncotarget 6: 19087-19101
24. Di Minin G, Bellazzo A, Dal Ferro M, Chiaruttini G, Nuzzo S, Bicciato S, Rami D, Bulla R, Sommaggio R, Rosato A, et al, (2014) Mutant p53 reprograms TNF signaling in cancer cells through interaction with the tumor suppressor DAB2IP. Mol Cell 56: 617-629
25. Zhang H, Liu C-Y, Zha Z-Y, Zhao B, Yao J, Zhao S, Xiong Y, Lei QY, Guan KL, (2009) TEAD transcription factors mediate the function of TAZ in cell growth and epithelial- mesenchymal transition. J Biol Chem 284: 13355-13362
26. Silwal-Pandit L, Vollan HK, Chin SF, Rueda OM, McKinney S, Osako T, Quigley DA, Kristensen VN, Aparicio S, Børresen-Dale AL, et al, (2014) TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. Clin Cancer Res 20: 3569-3580
27. Mantovani R, (1998) A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res 26: 1135-1143
28. Gurtner A, Starace G, Norelli G, Piaggio G, Sacchi A, Bossi G, (2010) Mutant p53-induced up-regulation of mitogen-activated protein kinase kinase 3 contributes to gain of function. J Biol Chem 285: 14160-14169
29. Liu K, Ling S, Lin WC, (2011) TopBP1 mediates mutant p53 gain of function through NF-Y and p63/p73. Mol Cell Biol 31: 4464-4481
30. Acin S, Li Z, Mejia O, Roop DR, El-Naggar AK, Caulin C, (2011) Gain-of-function mutant p53 but not p53 deletion promotes head and neck cancer progression in response to oncogenic K-ras. J Pathol 225: 479-489
31. Strano S, Munarriz E, Rossi M, Castagnoli L, Shaul Y, Sacchi A, Oren M, Sudol M, Cesareni G, Blandino G, (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276: 15164-15173
32. Sorrentino G, Ruggeri N, Specchia V, Cordenonsi M, Mano M, Dupont S, Manfrin A, Ingallina E, Sommaggio R, Piazza S, et al, (2014) Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 16: 357-366
33. Wang Z, Wu Y, Wang H, Zhang Y, Mei L, Fang X, Zhang X, Zhang F, Chen H, Liu Y, et al, (2014) Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility. Proc Natl Acad Sci USA 111: E89-E98
34. Sudol M, (1994) Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9: 2145-2152
35. Li Z, Zhao B, Wang P, Chen F, Dong Z, Yang H, Guan KL, Xu Y, (2010) Structural insights into the YAP and TEAD complex. Genes Dev 24: 235-240
36. Zhao B, Li L, Lei Q, Guan KL, (2010) The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 24: 862-874
37. Piccolo S, Dupont S, Cordenonsi M, (2014) The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev 94: 1287-1312
38. Strano S, Monti O, Pediconi N, Baccarini A, Fontemaggi G, Lapi E, Mantovani F, Damalas A, Citro G, Sacchi A, et al, (2005) The transcriptional coactivator Yes-associated protein drives p73 gene-target specificity in response to DNA Damage. Mol Cell 18: 447-459
39. Hong W, Guan KL, (2012) The YAP and TAZ transcription co-activators: key downstream effectors of the mammalian Hippo pathway. Semin Cell Dev Biol 23: 785-793
40. Varelas X, (2014) The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 141: 1614-1626
41. Comel A, Sorrentino G, Capaci V, Del Sal G, (2014) The cytoplasmic side of p53's oncosuppressive activities. FEBS Lett 588: 2600-2609
42. Cordenonsi M, Zanconato F, Azzolin L, Forcato M, Rosato A, Frasson C, Inui M, Montagner M, Parenti AR, Poletti A, et al, (2011) The Hippo transducer TAZ confers cancer stem cell-related traits on breast cancer cells. Cell 147: 759-772
43. Pece S, Tosoni D, Confalonieri S, Mazzarol G, Vecchi M, Ronzoni S, Bernard L, Viale G, Pelicci PG, Di Fiore PP, (2010) Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140: 62-73
44. Liu R, Wang X, Chen GY, Dalerba P, Gurney A, Hoey T, Sherlock G, Lewicki J, Shedden K, Clarke MF, (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. N Engl J Med 356: 217-226
45. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB, Harpole D, Lancaster JM, Berchuck A, et al, (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 439: 353-357
46. Zhao B, Ye X, Yu J, Li L, Li W, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al, (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22: 1962-1971
47. Dupont S, Morsut L, Aragona M, Enzo E, Giulitti S, Cordenonsi M, Zanconato F, Le Digabel J, Forcato M, Bicciato S, et al, (2011) Role of YAP/TAZ in mechanotransduction. Nature 474: 179-183
48. Mazzone M, Selfors LM, Albeck J, Overholtzer M, Sale S, Carroll DL, Pandya D, Lu Y, Mills GB, Aster JC, et al, (2010) Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc Natl Acad Sci USA 107: 5012-5017
49. Mackay A, Jones C, Dexter T, Silva RLA, Bulmer K, Jones A, Simpson P, Harris RA, Jat PS, Neville AM, et al, (2003) cDNA microarray analysis of genes associated with ERBB2 (HER2/neu) overexpression in human mammary luminal epithelial cells. Oncogene 22: 2680-2688
50. DiMeo TA, Anderson K, Phadke P, Fan C, Feng C, Perou CM, Naber S, Kuperwasser C, (2009) A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer. Cancer Res 69: 5364-5373
51. Padua D, Zhang XH-F, Wang Q, Nadal C, Gerald WL, Gomis RR, Massagué J, (2008) TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133: 66-77
52. Montagner M, Enzo E, Forcato M, Zanconato F, Parenti A, Rampazzo E, Basso G, Leo G, Rosato A, Bicciato S, et al, (2012) SHARP1 suppresses breast cancer metastasis by promoting degradation of hypoxia-inducible factors. Nature 487: 380-384
53. Park BK, Zhang H, Zeng Q, Dai J, Keller ET, Giordano T, Gu K, Shah V, Pei L, Zarbo RJ, et al, (2007) NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med 13: 62-69
54. Alvarez JV, Febbo PG, Ramaswamy S, Loda M, Richardson A, Frank DA, (2005) Identification of a genetic signature of activated signal transducer and activator of transcription 3 in human tumors. Cancer Res 65: 5054-5062
55. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al, (2005) An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102: 13550-13555
56. van de Wetering M, Sancho E, Verweij C, de Lau W, Oving I, Hurlstone A, van der Horn K, Batlle E, Coudreuse D, Haramis AP, et al, (2002) The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. Cell 111: 241-250
57. Smyth GK, (2005) Limma: linear models for microarray data. In Statistics for Biology and Health, Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, (eds), pp 397-420. New York: Springer
58. Yu G, Wang LG, Han Y, He QY, (2012) ClusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16: 284-287
59. Azzolin L, Zanconato F, Bresolin S, Forcato M, Basso G, Bicciato S, Cordenonsi M, Piccolo S, (2012) Role of TAZ as mediator of Wnt signaling. Cell 151: 1443-1456
60. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352.
61. Valenti F, Fausti F, Biagioni F, Shay T, Fontemaggi G, Domany E, Yaffe MB, Strano S, Blandino G, Di Agostino S, (2011) Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. Cell Cycle 10: 4330-4340
62. Fausti F, Di Agostino S, Cioce M, Bielli P, Sette C, Pandolfi PP, Oren M, Sudol M, Strano S, Blandino G, (2013) ATM kinase enables the functional axis of YAP, PML and p53 to ameliorate loss of Werner protein-mediated oncogenic senescence. Cell Death Differ 20: 1498-1509
63. Brummelkamp TR, Bernards R, Agami R, (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243-247
64. Shetty S, Velusamy T, Idell S, Shetty P, Mazar AP, Bhandary YP, Shetty RS, (2007) Regulation of urokinase receptor expression by p53: novel role in stabilization of uPAR mRNA. Mol Cell Biol 27: 5607-5618
65. Valenti F, Ganci F, Fontemaggi G, Sacconi A, Strano S, Blandino G, Di Agostino S, (2014) Gain of function mutant p53 proteins cooperate with E2F4 to transcriptionally downregulate RAD17 and BRCA1 gene expression. Oncotarget 6: 5547-5566